Veru Inc. (VERU)
VERUNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.17
+0.0275 (+1.28%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $37.34m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.04 to $7.33
- Average volume
- 198.3k
- Previous close
- $2.14
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $28.00, +1191.2% from here
Earnings
next estimate $-0.3400Next report Dec 16, 2026
Dec 2025
+44.7%
Mar 2026
+64.9%
Jun 2026
+6.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | $1.17m | -$5.42m | -$7.22m | -$7.71m |
| Net income | $1.45m | -$5.33m | -$2.74m | -$6.99m |
News
8 latest- Veru Advances Sabizabulin Toward Phase 2b Trial In Daraxonrasib-Resistant Pancreatic Cancer RTTNews · Sep 8, 2026
- Veru (VERU) Q3 2026 Earnings Call TranscriptThe Motley Fool · Aug 17, 2026
- Veru Gains 17% As Obesity Trial Exceeds Enrollment Target, Data Due In Q1, 2027 RTTNews · Aug 10, 2026
- Veru Completes Phase 2b Enrollment For Enobosarm In Treating Obesity RTTNews · Jul 28, 2026
- Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA... RTTNews · Jun 4, 2026
- Veru (VERU) Q2 2026 Earnings TranscriptThe Motley Fool · May 13, 2026
- Veru (VERU) Q1 2026 Earnings Call TranscriptThe Motley Fool · Feb 11, 2026
- Veru (VERU) Price Target Increased by 11.11% to 25.50Fintel · Feb 4, 2026
The company
Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and oncology. The Company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass to improve body composition and physical function which is expected to result in clinically meaningful incremental weight reduction versus GLP-1 RA therapy alone.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- verupharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.